Literature DB >> 25246498

Functional avidity-driven activation-induced cell death shapes CTL immunodominance.

Silvia Dalla Santa1, Anna Merlo1, Sara Bobisse2, Elisa Ronconi3, Daniela Boldrin1, Gabriella Milan4, Vito Barbieri5, Oriano Marin6, Antonella Facchinetti5, Giovanni Biasi7, Riccardo Dolcetti8, Paola Zanovello9, Antonio Rosato10.   

Abstract

Immunodominance is a complex phenomenon that relies on a mere numerical concept, while being potentially influenced at every step of the immune response. We investigated the mechanisms leading to the establishment of CTL immunodominance in a retroviral model and found that the previously defined subdominant Env-specific CD8(+) T cells are endowed with an unexpectedly higher functional avidity than is the immunodominant Gag-recognizing counterpart. This high avidity, along with the Env Ag overload, results in a supraoptimal TCR engagement. The overstimulation makes Env-specific T lymphocytes more susceptible to apoptosis, thus hampering their expansion and leading to an unintentional "immune kamikazing." Therefore, Ag-dependent, hyperactivation-induced cell death can be regarded as a novel mechanism in the establishment of the immunodominance that restrains and opposes the expansion of high-avidity T cells in favor of lower-affinity populations.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25246498     DOI: 10.4049/jimmunol.1303203

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  The Ankylosing Spondylitis-associated HLA-B*2705 presents a B*0702-restricted EBV epitope and sustains the clonal amplification of cytotoxic T cells in patients.

Authors:  Valentina Tedeschi; Carolina Vitulano; Alberto Cauli; Fabiana Paladini; Matteo Piga; Alessandro Mathieu; Rosa Sorrentino; Maria Teresa Fiorillo
Journal:  Mol Med       Date:  2016-05-18       Impact factor: 6.354

2.  Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.

Authors:  Marta Mazzocco; Matteo Martini; Antonio Rosato; Elisabetta Stefani; Andrea Matucci; Silvia Dalla Santa; Francesco De Sanctis; Stefano Ugel; Sara Sandri; Giovanna Ferrarini; Tiziana Cestari; Sergio Ferrari; Paola Zanovello; Vincenzo Bronte; Silvia Sartoris
Journal:  Immunology       Date:  2015-06-15       Impact factor: 7.397

Review 3.  Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Authors:  Victoria Hillerdal; Magnus Essand
Journal:  BioDrugs       Date:  2015-04       Impact factor: 5.807

4.  Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.

Authors:  Eva Bräunlein; Gaia Lupoli; Franziska Füchsl; Esam T Abualrous; Niklas de Andrade Krätzig; Dario Gosmann; Lukas Wietbrock; Sebastian Lange; Thomas Engleitner; Huan Lan; Stefan Audehm; Manuel Effenberger; Melanie Boxberg; Katja Steiger; Yinshui Chang; Kai Yu; Cigdem Atay; Florian Bassermann; Wilko Weichert; Dirk H Busch; Roland Rad; Christian Freund; Iris Antes; Angela M Krackhardt
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.